Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Immunoglobulin Light-chain Amyloidosis 3Multiple Myeloma 1

Interventions

Dexamethasone 98daratumumab 57Lenalidomide 53Bortezomib 38pomalidomide 37Cyclophosphamide 37carfilzomib 25Calcium Dobesilate 25fludarabine 22talquetamab 19iberdomide 18isatuximab 17Specimen Handling 17Magnetic Resonance Spectroscopy 17Biopsy 15selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Focal Adhesion Protein-Tyrosine Kinases × Plasma cell × Clear all
NCT05695508 2025-12-24

HD10/DSMMXX

University of Heidelberg Medical Center

Phase 2 Recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT07079423 2025-07-23

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06935162 2025-05-25

Teclistamab in Previously Treated AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06699394 2025-04-24

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Peking University People's Hospital

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡